TABLE 7.
Percentage change relative to baseline in blood creatinine (Δ%Cr) and potassium (Δ%K) concentrations and hematocrit (Δ%Hct) in proteinuric dogs randomized to receive enalapril or telmisartan, with or without the other study drug after day 90
| Variable | Study day | Enalapril group | Telmisartan group | P‐value | ||
|---|---|---|---|---|---|---|
| Value | n | Value | n | |||
| Δ%Cr | 7 | 9.6 ± 19.8 | 19 | 3.0 ± 20.1 | 20 | .32 |
| 30 | 11.0 ± 20.4 | 17 | 2.7 ± 21.5 | 20 | .24 | |
| 37 | 9.5 ± 27.1 | 14 | 10.1 ± 16.4 | 13 | .95 | |
| 67 | 14.3 ± 26.3 | 9 | 21.5 ± 22.7 | 9 | .54 | |
| 97 | 20.0 (5.9‐150.0) | 7 | 77.8 (4.5‐120.5) | 6 | .56 | |
| 120 (all dogs) | 15.6 (−23.1‐50.0) | 12 | 14.3 (−11.1‐88.9) | 13 | .70 | |
| 120 (monotherapy) | 13.1 ± 17.0 | 6 | 10.9 ± 16.6 | 10 | .81 | |
| 120 (combination therapy) | 23.7 ± 27.2 | 6 | 37.7 ± 49.1 | 3 | .67 | |
| Δ%K | 7 | 4.0 ± 9.7 | 19 | 3.5 ± 9.2 | 20 | .87 |
| 30 | 4.5 (−7.2‐37.5) | 17 | 3.3 (−9.5‐21.6) | 20 | .42 | |
| 37 | 5.0 ± 7.9 | 14 | 6.4 ± 5.3 | 13 | .59 | |
| 67 | 1.8 (−3.7‐31.6) | 9 | 6.2 (−8.0‐21.7) | 9 | .80 | |
| 97 | 13.8 ± 8.0 | 7 | 12.3 ± 9.8 | 6 | .84 | |
| 120 (all dogs) | 8.7 ± 11.7 | 12 | 5.4 ± 6.7 | 13 | .40 | |
| 120 (monotherapy) | 2.0 ± 10.6 | 6 | 3.6 ± 6.2 | 10 | .76 | |
| 120 (combination therapy) | 15.5 ± 9.0 | 6 | 11.4 ± 5.4 | 3 | .43 | |
| Δ%Hct | 7 | 0.0 (−13.9‐25.7) | 19 | −1.0 (−15.4‐9.4) | 20 | .73 |
| 30 | 0.0 (−13.3‐34.3) | 17 | −4.9 (−19.2‐6.5) | 20 | .06 | |
| 37 | −4.3 (−16.7‐42.9) | 14 | −9.4 (−23.1‐6.7) | 13 | .08 | |
| 67 | 3.1 ± 15.4 | 9 | −9.9 ± 10.1 | 9 | .05 | |
| 97 | 5.1 ± 13.0 | 7 | −12.1 ± 5.8 | 6 | .01 | |
| 120 (all dogs) | −2.9 ± 11.1 | 12 | −8.5 ± 11.9 | 13 | .25 | |
| 120 (monotherapy) | −6.8 ± 7.0 | 5 a | −5.4 ± 11.4 | 10 | .78 | |
| 120 (combination therapy) | 0.3 ± 13.4 | 6 | −18.7 ± 7.6 | 3 | .03 | |
Note: Data are presented as mean ± SD or median (range) where appropriate.
a
For 1 dog, hematocrit was not reported in the whole blood renal biochemical analysis performed at day 120.